Overview

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.

Phase:

PHASE2

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

cagrilintide
semaglutide